ID

14275

Descripción

Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00264849

Link

https://clinicaltrials.gov/show/NCT00264849

Palabras clave

Versiones (1)
  1. 7/4/16 7/4/16 -
Titular de derechos de autor

CC BY-NC 3.0

Subido en

7 de abril de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Asthma NCT00264849

Inglés

Eligibility Asthma NCT00264849

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT00264849
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients who met the following criteria were included:
Descripción

ID.1

Tipo de datos

boolean

males or females of any race, who were 12-75 years of age
Descripción

age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
a body weight ≥ 20 kg and ≤ 150 kg and with a total serum ige level ≥ 30 to ≤ 700 iu/ml
Descripción

body weight and serum ige level

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0005910
UMLS CUI [2]
C2229760
a diagnosis of allergic asthma ≥ 1 year duration according to american thoracic society (ats) criteria and at screening a history consistent with gina (2204) step 3 or 4 clinical features
Descripción

allergic asthma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0155877
UMLS CUI [1,2]
C0449238
a positive prick skin test (diameter of wheal >= 3 mm) to at least one perennial allergen documented within the past 2 years or taken at visit 1
Descripción

prick skin test

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0430561
increase in fev1 ≥12% over baseline value within 30 minutes of taking 2 to 4 puffs (2-4x100µg) salbutamol (albuterol) or nebulized salbutamol up to 5mg
Descripción

fev1

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0748133
UMLS CUI [1,2]
C0001927
an fev1 ≥ 40 and ≤ 80% of the predicted normal value for the patient at randomization
Descripción

fev1

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0748133
receiving moderate to high dose inhaled corticosteroid ≥ 800 µg bdp or equivalent and a regular inhaled long acting b-2 agonists for at least 3 months prior to screening and > 1000 µg (bdp) and a laba for at least 4 weeks during the run-in and at randomization
Descripción

inhaled corticosteroid, inhaled long acting beta2 agonists, bdp, laba

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0586793
UMLS CUI [2]
C2936789
patients who have suffered multiple (i.e. at least two) independent documented severe asthma exacerbations while receiving high doses of ics (≥ 800 µg bdp or equivalent) plus regular inhaled laba
Descripción

asthma exacerbation

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0349790
UMLS CUI [2]
C3248292
UMLS CUI [3,1]
C2936789
UMLS CUI [3,2]
C0040223
evidence of poor asthma control at screening (based on patient history) and for at least 4 weeks immediately prior to randomisation
Descripción

poor asthma control

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0004096
UMLS CUI [1,2]
C2700379
UMLS CUI [1,3]
C2587213
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who met the following criteria were excluded:
Descripción

ID.11

Tipo de datos

boolean

had received systemic corticosteroids for reasons other than asthma within 4 weeks of visit 1
Descripción

systemic corticosteroids

Tipo de datos

boolean

Alias
UMLS CUI [1]
C4039704
a smoking history >10 pack years
Descripción

smoking history

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1519384
UMLS CUI [2]
C1277691
an active lung disease other than allergic asthma
Descripción

lung disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0024115
elevated serum ige levels for reasons other than allergy
Descripción

serum ige levels

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2229760
patients with significant underlying medical conditions
Descripción

significant underlying medical conditions

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009488
Volver a la parte superior de la página

Similar models

Eligibility Asthma NCT00264849

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT00264849
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients who met the following criteria were included:
boolean
age
Item
males or females of any race, who were 12-75 years of age
boolean
C0001779 (UMLS CUI [1])
body weight and serum ige level
Item
a body weight ≥ 20 kg and ≤ 150 kg and with a total serum ige level ≥ 30 to ≤ 700 iu/ml
boolean
C0005910 (UMLS CUI [1])
C2229760 (UMLS CUI [2])
allergic asthma
Item
a diagnosis of allergic asthma ≥ 1 year duration according to american thoracic society (ats) criteria and at screening a history consistent with gina (2204) step 3 or 4 clinical features
boolean
C0155877 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
prick skin test
Item
a positive prick skin test (diameter of wheal >= 3 mm) to at least one perennial allergen documented within the past 2 years or taken at visit 1
boolean
C0430561 (UMLS CUI [1])
fev1
Item
increase in fev1 ≥12% over baseline value within 30 minutes of taking 2 to 4 puffs (2-4x100µg) salbutamol (albuterol) or nebulized salbutamol up to 5mg
boolean
C0748133 (UMLS CUI [1,1])
C0001927 (UMLS CUI [1,2])
fev1
Item
an fev1 ≥ 40 and ≤ 80% of the predicted normal value for the patient at randomization
boolean
C0748133 (UMLS CUI [1])
inhaled corticosteroid, inhaled long acting beta2 agonists, bdp, laba
Item
receiving moderate to high dose inhaled corticosteroid ≥ 800 µg bdp or equivalent and a regular inhaled long acting b-2 agonists for at least 3 months prior to screening and > 1000 µg (bdp) and a laba for at least 4 weeks during the run-in and at randomization
boolean
C0586793 (UMLS CUI [1])
C2936789 (UMLS CUI [2])
asthma exacerbation
Item
patients who have suffered multiple (i.e. at least two) independent documented severe asthma exacerbations while receiving high doses of ics (≥ 800 µg bdp or equivalent) plus regular inhaled laba
boolean
C0349790 (UMLS CUI [1])
C3248292 (UMLS CUI [2])
C2936789 (UMLS CUI [3,1])
C0040223 (UMLS CUI [3,2])
poor asthma control
Item
evidence of poor asthma control at screening (based on patient history) and for at least 4 weeks immediately prior to randomisation
boolean
C0004096 (UMLS CUI [1,1])
C2700379 (UMLS CUI [1,2])
C2587213 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
ID.11
Item
patients who met the following criteria were excluded:
boolean
systemic corticosteroids
Item
had received systemic corticosteroids for reasons other than asthma within 4 weeks of visit 1
boolean
C4039704 (UMLS CUI [1])
smoking history
Item
a smoking history >10 pack years
boolean
C1519384 (UMLS CUI [1])
C1277691 (UMLS CUI [2])
lung disease
Item
an active lung disease other than allergic asthma
boolean
C0024115 (UMLS CUI [1])
serum ige levels
Item
elevated serum ige levels for reasons other than allergy
boolean
C2229760 (UMLS CUI [1])
significant underlying medical conditions
Item
patients with significant underlying medical conditions
boolean
C0009488 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial